2022 press releases
- Servier and Gustave Roussy sign a framework agreement for a strategic collaboration in oncology and immuno-oncology
Press release, 14th december 2022 - The Paris Saclay Cancer Cluster is the laureate of the “France 2030” Biocluster plan
Press release, 5th december 2022 - ESMO 2022 - Internal vectorised radiotherapy is effective in neuroendocrine tumours of the pancreas
Press release, 12th september 2022 - ESMO 2022 - First highly-targeted therapy against the FGFR2 gene in biliary tract cancer
Press release, 11th septembre 2022 - ESMO 2022 - Three-quarters of women aged less than 40 treated by chemotherapy for localised breast cancer re-establish their menstrual cycles
Press release, 11th september 2022 - Professor Fabrice André is President-elect of the European Society for Medical Oncology (ESMO)
Press release, 1st july 2022 - ORPHELIA Pharma and Gustave Roussy announce the publication in Pharmaceuticals of the scientific work related to the development of the first temozolomide oral suspension for children
Press release, 9 june 2022 - ASCO 2022 - “2 in 1” immunotherapy in advanced kidney cancer
Press release, 7 june 2022 - ASCO 2022 - The SACHA study supports the use of innovative anticancer therapies in children outside clinical trials
Press release, 7 june 2022 - ASCO 2022 - RAGNAR study: the benefits of targeted therapy beyond bladder cancer
Press release, 7 june 2022 - ASCO 2022 - A promising targeted therapy for treatment of relapses of acute myeloid leukaemia
Press release, 7 june 2022 - Dana-Farber Cancer Institute, Gustave Roussy, and L’Institut Servier sign an oncology cooperation agreement
Press release, 7 june 2022 - 2002-2022: DOSIsoft delivering 20 years of Innovation
Press release, 5 may 2022 - The Paris Saclay Cancer Cluster association announces its official creation and the appointment of leaders - A global ambition for French oncology
Press release, 4 february 2022 - Cancer Treatment: Identification of the Blood Vessels That Allow Killer Lymphocytes to Access and Destroy Tumors
Press release, 3 february 2022
Catégorie de la page:
